+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Multiple Sclerosis - Global Drug Forecast and Market Analysis to 2028

  • ID: 4898063
  • Report
  • December 2019
  • Region: Global
  • 356 pages
  • GlobalData
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 3

FEATURED COMPANIES

  • AB Science
  • Avadel Pharmaceuticals
  • Celgene
  • Jannsen
  • Merck Serono
  • Sanofi
  • MORE
Multiple Sclerosis - Global Drug Forecast and Market Analysis to 2028

Summary

Multiple Sclerosis (MS) therapeutics market has entered an exciting phase, with an upsurge of available treatment options and several promising late-stage pipeline products offering diverse mechanisms of action (MOA). The latest research report “Multiple Sclerosis: Global Drug Forecast and Market Analysis to 2028” expects the Multiple Sclerosis (MS) market to grow in sales from $19.8bn in 2018 to $32.9bn in 2028 with a compound annual growth rate (CAGR) of 5.2%, due to the launch of 11 new pipeline agents providing more options for patients and stimulating further competition.

Multiple Sclerosis (MS) is a primary autoimmune disease with a mechanism involving recurrent inflammatory attacks on the central nervous system (CNS) due to a dysfunctional immune system, leading to neurological disability. Multiple Sclerosis (MS) is primarily considered an inflammatory demyelinating disorder of the CNS, and is characterized by lymphocyte and macrophage infiltrates, as well as glial cell activation. Multiple Sclerosis (MS) patients are generally grouped into four major categories on the basis of the disease course. These categories are Relapse-Remitting Multiple Sclerosis (RRMS), Secondary Progressive Multiple Sclerosis (SPMS), Primary Progressive Multiple Sclerosis (PPMS), and Progressive Relapsing Multiple Sclerosis (PRMS).

The Multiple Sclerosis (MS) pipeline is strong and diverse with a total of 49 products in all stages and phases of clinical development, of which 24 are early-stage and 25 are in the late-stage pipeline. Progressive Multiple Sclerosis (MS) is a significant focus for product development, with seven of the late-stage products targeting this patient group as an initial indication. There is currently a distinct lack of Disease Modifying Therapies (DMT) options for patients with progressive Multiple Sclerosis (MS) subtypes, and these populations remain significantly underserved.

The 11 new pipeline agents have a broad range of MOA, including anti-CD20 antibodies, three second generation S1P receptor modulators, an anti-LINGO-1 antibody, a tyrosine kinase inhibitor, a Repulsive Guidance Molecule A (RGMA) Inhibitor and antioxidants. Further, 14 late-stage drug products will launch in the seven major markets (7MM - US, France, Germany, Italy, Spain, UK and Japan) during, or shortly after, the forecast period from 2018 to 2028.

While physicians might be persuaded that there may be some advantages of the newer generation, the pipeline developers may find it difficult to persuade payers, or insurance companies to use their drug over fingolimod generics, especially in the US, where branded drug prices are high.

The current Multiple Sclerosis (MS) market is highly competitive, with 14 available treatment options, most of which are immunomodulatory agents. The majority of approved treatments address the inflammatory and systemic origins of the disease, but few possess neuroprotective effects and, as such, have an insufficient impact on the underlying neurologic deterioration caused by Multiple Sclerosis (MS). Remyelination strategies could prove revolutionary for Multiple Sclerosis (MS), as they address a key pathophysiological aspect of the disease that is thought to contribute to the accrual of permanent disability.

The Multiple Sclerosis (MS) market is heading towards earlier and more aggressive therapies, with studies in the US questioning whether people with Multiple Sclerosis (MS) who are recently diagnosed should already go on with one of the monoclonal antibody therapies.

Scope
  • Overview of Multiple Sclerosis, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and disease management.
  • Annualized Multiple Sclerosis therapeutics market revenue, cost of therapy per patient, and treatment usage patterns in three patient segments (RRMS, SPMS and PPMS) forecast from 2018 to 2028.
  • Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the Multiple Sclerosis therapeutics market
  • Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for Multiple Sclerosis therapy. The most promising candidates in Phase III development are profiled.
  • Analysis of the current and future market competition in the global Multiple Sclerosis therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
Reasons to buy

The report will enable you to -
  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
  • Develop business strategies by understanding the trends shaping and driving the global Multiple Sclerosis therapeutics market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global Multiple Sclerosis therapeutics market in the future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • AB Science
  • Avadel Pharmaceuticals
  • Celgene
  • Jannsen
  • Merck Serono
  • Sanofi
  • MORE
1 Executive Summary
1.1 Moderate Growth Expected in the MS Market from 2018 to 2028
1.2 R&D and Corporate Strategies Within the MS Market
1.3 Current Treatments Leave a High Level of Unmet Need in the MS Market
1.4 Opportunities Remain for Products that Fulfill Significant Unmet Needs in the MS Market
1.5 Late-Stage Pipeline Drugs Entering the MS Market Will Be a Key Driver of Growth
1.6 What Do the Physicians Think?

2 Introduction
2.1 Catalyst
2.2 Related Reports

3 Disease Overview
3.1 Etiology and Pathophysiology
3.1.1 Etiology
3.1.2 Pathophysiology
3.2 Classification
3.2.1 Relapsing-Remitting MS
3.2.2 Secondary Progressive MS
3.2.3 Primary Progressive MS
3.2.4 Progressive Relapsing MS
3.3 Symptoms
3.4 Prognosis
3.5 Quality of Life

4 Epidemiology
4.1 Disease Background
4.2 Risk Factors and Comorbidities
4.3 Global and Historical Trends
4.4 Forecast Methodology
4.4.1 Sources
4.4.2 Forecast Assumptions and Methods
4.5 Epidemiological Forecast for MS (2018-2028)
4.5.1 Diagnosed Incident Cases of MS
4.5.2 Age-Specific Diagnosed Incident Cases of MS
4.5.3 Sex-Specific Diagnosed Incident Cases of MS
4.5.4 Diagnosed Prevalent Cases of MS
4.5.5 Age-Specific Diagnosed Prevalent Cases of MS
4.5.6 Sex-Specific Diagnosed Prevalent Cases of MS
4.5.7 Diagnosed Prevalent Cases of MS by Type
4.6 Discussion
4.6.1 Epidemiological Forecast Insight
4.6.2 Limitations of Analysis
4.6.3 Strengths of Analysis

5 Disease Management

6 Competitive Assessment

7 Unmet Needs and Opportunity Assessment

8 Pipeline Assessment

9 Current and Future Players

10 Market Outlook

11 Appendix

List of Tables
Table 1: Multiple Sclerosis: Key Metrics in the Seven Major Pharmaceutical Markets
Table 2: Common Presenting Symptoms of MS
Table 3: Factors That Can Affect Prognosis in MS
Table 4: Risk Factors and Comorbid Conditions Associated with MS
Table 5: Revised 2017 McDonald Criteria for the Diagnosis of MS
Table 6: Treatment Guidelines for MS
Table 7: Top Three Disease-Modifying Therapies Prescribed for MS, by Market, 2018
Table 8: Pharmacotherapy for Common MS Symptoms
Table 9: US - MS Diagnosis Metrics
Table 10: US - MS Treatment Metrics
Table 11: France - MS Diagnosis Metrics
Table 12: France - MS Treatment Metrics
Table 13: Germany - MS Diagnosis Metrics
Table 14: Germany - MS Treatment Metrics
Table 15: Italy - MS Diagnosis Metrics
Table 16: Italy - MS Treatment Metrics
Table 17: Spain - MS Diagnosis Metrics
Table 18: Spain - MS Treatment Metrics
Table 19: UK - MS Diagnosis Metrics
Table 20: UK - MS Treatment Metrics
Table 21: Japan - MS Diagnosis Metrics
Table 22: Japan - MS Treatment Metrics
Table 23: Leading Disease-Modifying Drugs for the Treatment of MS, 2019
Table 24: Product Profile - Betaseron
Table 25: Efficacy Results for Betaseron in a Phase III (IFNBMS) Trial
Table 26: Betaseron SWOT Analysis, 2019
Table 27: Product Profile - Avonex
Table 28: Efficacy Results for Avonex in a Phase III Trial
Table 29: Avonex SWOT Analysis, 2019
Table 30: Product Profile - Rebif
Table 31: Rebif SWOT Analysis, 2019
Table 32: Product Profile - Plegridy
Table 33: Clinical and MRI Endpoints at Year 1 from a Phase III Trial of Plegridy in MS
Table 34: Clinical and MRI Endpoints at Year 2 from a Phase III Trial of Plegridy in MS
Table 35: AEs During Year 1 of a Phase III Trial of Plegridy in MS
Table 36: Plegridy SWOT Analysis, 2019
Table 37: Product Profile - Copaxone
Table 38: Copaxone SWOT Analysis, 2019
Table 39: Product Profile - Tysabri
Table 40: Efficacy Results for Tysabri in a Phase III (DECIDE) Trial
Table 41: Tysabri SWOT Analysis, 2019
Table 42: Product Profile - Lemtrada
Table 43: Efficacy Results for Lemtrada in a CARE II Extension Trial
Table 44: Lemtrada SWOT Analysis, 2019
Table 45: Product Profile - Ocrevus
Table 46: Efficacy Results for Ocrevus in a Phase III (OPERA I and OPERA II) MS Trial
Table 47: Efficacy Results for Ocrevus in Phase III (OPERA I and OPERA II) MS Trials
Table 48: Efficacy Results for Ocrevus in Phase III (OPERA OLE) MS Trials
Table 49: Efficacy Results for Ocrevus in Phase III (ORATORIO OLE) MS Trials
Table 50: Safety Results for Ocrevus in Phase III (OPERA I and OPERA II) MS Trials
Table 51: Safety Results for Ocrevus in Phase III (ORATARIO) MS Trials
Table 52: Ocrevus SWOT Analysis, 2019
Table 53: Product Profile - Gilenya
Table 54: Gilenya SWOT Analysis, 2019
Table 55: Product Profile - Aubagio
Table 56: Aubagio SWOT Analysis, 2019
Table 57: Product Profile - Tecfidera
Table 58: Tecfidera SWOT Analysis, 2019
Table 59: Product Profile - Mavenclad
Table 60: Efficacy Results for Mavenclad in a Phase III (CLARITY and CLARITY EXTENSION) MS Trial

List of Figures
Figure 1: Sales for MS by Region, 2018-2028
Figure 2: Company Portfolio Gap Analysis in MS, 2018-2028
Figure 3: Competitive Assessment of Late-Stage Pipeline Agents in MS, 2018-2028
Figure 4: Accrual of Disability in the Four Subtypes of MS
Figure 5: 7MM, Diagnosed Incidence of MS (Cases per 100,000 Population), Men and Women, All Ages, 2018
Figure 6: 7MM, Diagnosed Prevalence of MS (%), Men and Women, All Ages, 2018
Figure 7: 7MM, Sources Used and Not Used to Forecast the Diagnosed Incident Cases of MS
Figure 8: 7MM, Sources Used and Not Used to Forecast the Diagnosed Prevalent Cases of MS
Figure 9: 7MM, Sources Used and Not Used to Forecast the Diagnosed Prevalent Cases of MS by Type
Figure 10: 7MM, Diagnosed Incident Cases of MS, N, Both Sexes, All Ages, 2018
Figure 11: 7MM, Age-Specific Diagnosed Incident Cases of MS, N, Both Sexes, All Ages, 2018
Figure 12: 7MM, Sex-Specific Diagnosed Incident Cases of MS, N, All Ages, 2018
Figure 13: 7MM, Diagnosed Prevalent Cases of MS, N, Both Sexes, All Ages, 2018
Figure 14: 7MM, Age-Specific Diagnosed Prevalent Cases of MS, N, Both Sexes, All Ages, 2018
Figure 15: 7MM, Sex-Specific Diagnosed Prevalent Cases of MS, N, All Ages, 2018
Figure 16: 7MM, Diagnosed Prevalent Cases of MS by Type, N, Both Sexes, All Ages, 2018
Figure 17: EDSS
Figure 18: Algorithm for the Treatment of MS with DMTs
Figure 19: Overview of the Unmet Needs in MS
Figure 20: Overview of the Development Pipeline in MS
Figure 21: MS Therapeutics - Clinical Trials by Country, 2019
Figure 22: MS - Phase II-III Pipeline, 2019
Figure 23: Competitive Assessment of Late-Stage Pipeline Agents in MS, 2018-2028
Figure 24: Company Portfolio Gap Analysis in MS, 2018-2028
Figure 25: Global Sales for MS by Region, 2018-2028
Figure 26: Global Sales for MS by Therapy Type, 2018-2028
Figure 27: Sales for MS in the US by Therapy Type, 2018-2028
Figure 28: Sales for MS in the 5EU by Therapy Type, 2018-2028
Figure 29: Sales for MS in Japan by Therapy Type, 2018-2028
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • Teva
  • Roche
  • TG Therapeutics
  • Avadel Pharmaceuticals
  • GSK
  • GeNeuro
  • Biogen
  • AbbVie
  • Celgene
  • Actelion
  • Jannsen
  • AB Science
  • MedDay
  • MediciNova
  • Merck Serono
  • Sanofi
  • Bayer
  • Novartis
Note: Product cover images may vary from those shown
Adroll
adroll